0001209191-23-045439.txt : 20230811 0001209191-23-045439.hdr.sgml : 20230811 20230811162438 ACCESSION NUMBER: 0001209191-23-045439 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230810 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lang Matthew CENTRAL INDEX KEY: 0001712069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 231164483 MAIL ADDRESS: STREET 1: C/O MYOVANT SCIENCES INC. STREET 2: 2000 SIERRA POINT PARKWAY, 9TH FLOOR CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 201 HASKINS WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-08-10 0 0001806952 Lyell Immunopharma, Inc. LYEL 0001712069 Lang Matthew C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY SOUTH SAN FRANICSCO CA 94080 0 1 0 0 Chief Business Officer 0 Option (right to buy) 2.31 2023-08-10 4 A 0 2250000 0.00 A 2033-08-09 Common Stock 2250000 2250000 D 1/4 of the option shares shall vest on July 1, 2024, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. /s/ Matthew Lang 2023-08-11